ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2023-4-174-187ssmu-5434Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESЛипидомные маркеры ожирения и их динамика после бариатрических операцийLipidomic markers of obesity and their dynamics after bariatric surgeryhttps://orcid.org/0000-0001-9011-8720СапринаТ. В.SaprinaT. V.

Саприна Татьяна Владимировна – д-р мед. наук, профессор кафедры факультетской терапии с курсом клинической фармакологии, зав. эндокринологической клиникой 

634050, г. Томск, Московский тракт, 2

2, Moscow Trakt, Tomsk, 634050

tanja.v.saprina@mail.ruhttps://orcid.org/0000-0002-4441-821XБашироваА. С.BashirovaA. S.

Баширова Анжелика Сергеевна – студентка, лечебный факультет

634050, г. Томск, Московский тракт, 2

2, Moscow Trakt, Tomsk, 634050

bashirova.as@mail.ruhttps://orcid.org/0000-0001-9348-4945ИвановВ. В.IvanovV. V.

Иванов Владимир Владимирович – канд. биол. наук, руководитель Центра доклинических исследований

634050, г. Томск, Московский тракт, 2

2, Moscow Trakt, Tomsk, 634050

ivanovvv1953@gmail.comhttps://orcid.org/0000-0002-9622-3457ПековС. И.PekovS. I.

Пеков Станислав Игоревич – канд. хим. наук, ст. науч. сотрудник, лаборатория молекулярной медицинской диагностики, МФТИ

634050, г. Томск, Московский тракт, 2,

121205, г. Москва, Большой бульвар 30, стр. 1,

115184, г. Москва, Климентовский пер., 1 стр. 1

2, Moscow Trakt, Tomsk, 634050,

30, Bolshoy Boulevard, Bld. 1, Moscow, 121205,

1, Klimentovsky Str., Bld. 1, Moscow, 115184

stanislav.pekov@forwe.ruhttps://orcid.org/0000-0002-5904-2470ПоповИ. А.PopovI. A.

Попов Игорь Алексеевич – канд. физ.-мат. наук, зав. лабораторией молекулярной медицинской диагностики, МФТИ

634050, г. Томск, Московский тракт, 2,

115184, г. Москва, Климентовский пер., 1 стр. 1

2, Moscow Trakt, Tomsk, 634050,

1, Klimentovsky Str., Bld. 1, Moscow, 115184

popov.ia@ssmu.ruhttps://orcid.org/0000-0001-6381-1327БашировС. Р.BashirovS. R.

Баширов Сергей Рафаэльевич – д-р мед. наук, зав. кафедрой общей хирургии

634050, г. Томск, Московский тракт, 2

2, Moscow Trakt, Tomsk, 634050

bars-tomsk@rambler.ruhttps://orcid.org/0009-0004-7992-9556ВасильеваЕ. А.VasilyevaE. A.

Васильева Елизавета Алексеевна – аспирант, кафедра общей хирургии

634050, г. Томск, Московский тракт, 2

2, Moscow Trakt, Tomsk, 634050

elizaveta.liza29@mail.ruhttps://orcid.org/0000-0001-6766-3974ПавленкоО. А.PavlenkoO. A.

Павленко Ольга Алексеевна – д-р мед. наук, профессор кафедры факультетской терапии с курсом клинический фармакологии

634050, г. Томск, Московский тракт, 2

2, Moscow Trakt, Tomsk, 634050

pavlenko.51@mail.ruhttps://orcid.org/0000-0001-5295-3151КриницкийД. В.KrinitskiiD. V.

Криницкий Даниил Вадимович – студент, лечебный факультет

634050, г. Томск, Московский тракт, 2

2, Moscow Trakt, Tomsk, 634050

artel197@mail.ruhttps://orcid.org/0009-0006-4278-831XЧэньМ.ChenM.

Чэнь Максим – ординатор, кафедра факультетской терапии с курсом клинической фармакологии

634050, г. Томск, Московский тракт, 2

2, Moscow Trakt, Tomsk, 634050

maximchen.98@mail.ruСибирский государственный медицинский университет (СибГМУ)РоссияSiberian State Medical UniversityRussian FederationСибирский государственный медицинский университет (СибГМУ); Сколковский институт науки и технологий; Московский физико-технический институт (МФТИ)РоссияSiberian State Medical University; Skolkovo Institute of Science and Technology; Moscow Institute of Physics and TechnologyRussian FederationСибирский государственный медицинский университет (СибГМУ); Московский физико-технический институт (МФТИ)РоссияSiberian State Medical University; Moscow Institute of Physics and TechnologyRussian Federation202324012024224174187Copyright © Саприна Т.В., Баширова А.С., Иванов В.В., Пеков С.И., Попов И.А., Баширов С.Р., Васильева Е.А., Павленко О.А., Криницкий Д.В., Чэнь М., 20242024Саприна Т.В., Баширова А.С., Иванов В.В., Пеков С.И., Попов И.А., Баширов С.Р., Васильева Е.А., Павленко О.А., Криницкий Д.В., Чэнь М.Saprina T.V., Bashirova A.S., Ivanov V.V., Pekov S.I., Popov I.A., Bashirov S.R., Vasilyeva E.A., Pavlenko O.A., Krinitskii D.V., Chen M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/5434

Ожирение рассматривается как хроническое прогрессирующее заболевание, гетерогенное по своей этиологии и клиническим проявлениям, характеризующееся избыточным и отложением жировой массы в организме. Под термином «морбидное ожирение» понимают избыточное отложение жировой ткани с индексом массы тела (ИМТ) ≥ 40 кг/м2 или с ИМТ ≥ 35 кг/м2 при наличии серьезных осложнений, связанных с ожирением. Одновременно с ожирением возросла частота тесно ассоциированных с ним сахарного диабета второго типа и сердечно-сосудистых заболеваний, представляющих собой итог прогрессирования метаболических нарушений, в том числе инсулинорезистентности, которая неразрывно связана с накоплением висцерального жира и играет ключевую роль в патогенезе сопряженных с ожирением заболеваний.

Исследование липидомных сигнатур при ожирении и ассоциированных с ним состояний – перспективный раздел фундаментальной медицины, позволяющий существенно и на новом понятийном уровне стратифицировать когорту пациентов с ожирением на различные фенотипы, в том числе на метаболически здоровый и нездоровый фенотип. Динамические изменения липидома, как на фоне диетических воздействий, медикаментозного лечения, так и после различных бариатрических операций, также интересны с точки зрения разработки персонализированных стратегий лечения данного заболевания. Имеющиеся на данный момент исследования и их результаты позволяют считать, что мы находимся только в самом начале этого перспективного биомедицинского направления.

Obesity is considered as a chronic progressive disease, heterogeneous in its etiology and clinical manifestations, and characterized by excess in body fat mass and its deposition in the body. The term “morbid obesity” refers to excessive deposition of adipose tissue with a body mass index (BMI) ≥40 kg / m2 or with a BMI ≥ 35 kg / m2 in the presence of serious complications associated with obesity. Along with obesity, the frequency of type 2 diabetes mellitus and cardiovascular diseases closely associated with it has increased. It results from the progression of metabolic disorders, including insulin resistance, which is inextricably linked with the accumulation of visceral fat and plays a key role in the pathogenesis of obesity-related diseases.

The study of lipidomic signatures in obesity and associated conditions is a promising branch of fundamental medicine, which makes it possible to significantly and at a new conceptual level stratify a cohort of obese patients into various phenotypes, including a metabolically healthy and metabolically unhealthy obesity phenotypes. Dynamic changes in the lipidome both in the context of diet, drug treatment, and after various bariatric surgeries are of great interest for developing personalized strategies for the treatment of this disease. Currently available studies and their results suggest that we are only at the very start of studying this promising biomedical field.

ожирениемасс-спектрометрияметаболические профилированиелипидомлипидыклинические маркерыбиомаркерыбариатрияobesitymass spectrometrymetabolic profilinglipidomelipidsclinical markersbiomarkersbariatric surgeryReferencesWHO. Fact Sheet–Obesity and Overweight. updated 2021.6.9 (2021). URL: from: https://www.who.int/news-room/factsheets/detail/obesity-and-overweight (Accessed September 3, 2020).WHO. Fact Sheet–Obesity and Overweight. updated 2021.6.9 (2021). URL: from: https://www.who.int/news-room/factsheets/detail/obesity-and-overweight (Accessed September 3, 2020).Stevens V.L., Carter B.D., McCullough M.L., Campbell P.T., Wang Y. Metabolomic profiles associated with BMI, waist circumference, and diabetes and inflammation biomarkers in women. Obesity (Silver Spring). 2020 Jan.;28(1):187–196. DOI: 10.1002/oby.22670.Stevens V.L., Carter B.D., McCullough M.L., Campbell P.T., Wang Y. Metabolomic profiles associated with BMI, waist circumference, and diabetes and inflammation biomarkers in women. Obesity (Silver Spring). 2020 Jan.;28(1):187–196. DOI: 10.1002/oby.22670.Kliemann N., Viallon V., Murphy N., Beeken R.J., Rothwell J.A., Rinaldi S. et al. Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the european prospective investigation into cancer and nutrition. BMC Med. 2021Apr.30;19(1):101. DOI: 10.1186/s12916-021-01970-1.Kliemann N., Viallon V., Murphy N., Beeken R.J., Rothwell J.A., Rinaldi S. et al. Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the european prospective investigation into cancer and nutrition. BMC Med. 2021Apr.30;19(1):101. DOI: 10.1186/s12916-021-01970-1.Wang C., Wang M., Han X. Applications of mass spectrometry for cellular lipid analysis. Mol. Biosyst. 2015;11(3):698–713. DOI: 10.1039/C4MB00586D.Wang C., Wang M., Han X. Applications of mass spectrometry for cellular lipid analysis. Mol. Biosyst. 2015;11(3):698–713. DOI: 10.1039/C4MB00586D.Pekov S.I., Sorokin A.A., Kuzin A.A., Bocharov K.V., Bormotov D.S., Shivalin A.S. et al. Analysis of phosphatidylcholines alterations in human glioblastomas ex vivo. Biochem. Suppl. Ser. B Biomed. Chem. 2021;15(3):241–247. DOI: 10.1134/S1990750821030070.Pekov S.I., Sorokin A.A., Kuzin A.A., Bocharov K.V., Bormotov D.S., Shivalin A.S. et al. Analysis of phosphatidylcholines alterations in human glioblastomas ex vivo. Biochem. Suppl. Ser. B Biomed. Chem. 2021;15(3):241–247. DOI: 10.1134/S1990750821030070.Liebisch G., Fahy E., Aoki J., Dennis E.A., Durand T., Ejsing C.S. et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J. Lipid Res. 2020Dec.;61(12):1539–1555. DOI: 10.1194/jlr.S120001025.Liebisch G., Fahy E., Aoki J., Dennis E.A., Durand T., Ejsing C.S. et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J. Lipid Res. 2020Dec.;61(12):1539–1555. DOI: 10.1194/jlr.S120001025.Lytrivi M., Castell A.L., Poitout V., Cnop M. Recent insights into mechanisms of β-cell lipo- and glucolipotoxicity in type 2 diabetes. J. Mol. Biol. 2020March;432(5):1514–1534. DOI: 10.1016/j.jmb.2019.09.016.Lytrivi M., Castell A.L., Poitout V., Cnop M. Recent insights into mechanisms of β-cell lipo- and glucolipotoxicity in type 2 diabetes. J. Mol. Biol. 2020March;432(5):1514–1534. DOI: 10.1016/j.jmb.2019.09.016.Yoon H., Shaw J.L., Haigis M.C., Greka A. Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity. Mol. Cell. 2021Sept.16;81(18):3708–3730. DOI: 10.1016/j.molcel.2021.08.027.Yoon H., Shaw J.L., Haigis M.C., Greka A. Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity. Mol. Cell. 2021Sept.16;81(18):3708–3730. DOI: 10.1016/j.molcel.2021.08.027.Felix J.B., Cox A.R., Hartig S.M. Acetyl-coa and metabolite fluxes regulate white adipose tissue expansion. Trends Endocrinol. Metab. 2021May;32(5):320–332. DOI: 10.1016/j.tem.2021.02.008.Felix J.B., Cox A.R., Hartig S.M. Acetyl-coa and metabolite fluxes regulate white adipose tissue expansion. Trends Endocrinol. Metab. 2021May;32(5):320–332. DOI: 10.1016/j.tem.2021.02.008.Rahman M.N., Diantini A., Fattah M., Barliana M.I., Wijaya A. A highly sensitive, simple, and fast gas chromatography-mass spectrometry method for the quantification of serum shortchain fatty acids and their potential features in central obesity. Anal. Bioanal. Chem. 2021Nov.;413(27):6837–6844. DOI: 10.1007/s00216-021-03639-3.Rahman M.N., Diantini A., Fattah M., Barliana M.I., Wijaya A. A highly sensitive, simple, and fast gas chromatography-mass spectrometry method for the quantification of serum shortchain fatty acids and their potential features in central obesity. Anal. Bioanal. Chem. 2021Nov.;413(27):6837–6844. DOI: 10.1007/s00216-021-03639-3.Rangel-Huerta O.D., Pastor-Villaescusa B., Gil A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics. 2019;June13;15(6):93. DOI: 10.1007/s11306-019-1553-y.Rangel-Huerta O.D., Pastor-Villaescusa B., Gil A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics. 2019;June13;15(6):93. DOI: 10.1007/s11306-019-1553-y.Park S., Sadanala K.C., Kim E.K. A Metabolomic approach to understanding the metabolic link between obesity and diabetes. Mol. Cells. 2015July;38(7):587–596. DOI: 10.14348/molcells.2015.0126.Park S., Sadanala K.C., Kim E.K. A Metabolomic approach to understanding the metabolic link between obesity and diabetes. Mol. Cells. 2015July;38(7):587–596. DOI: 10.14348/molcells.2015.0126.Ho J.E., Larson M.G., Ghorbani A., Cheng S., Chen M.H., Keyes M. et al. Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes. PLoS One. 2016Feb.10;11(2):e0148361. DOI: 10.1371/journal.pone.0148361.Ho J.E., Larson M.G., Ghorbani A., Cheng S., Chen M.H., Keyes M. et al. Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes. PLoS One. 2016Feb.10;11(2):e0148361. DOI: 10.1371/journal.pone.0148361.Lope V., Del Pozo M.D.P., Lope V., Criado-Navarro I., Pastor-Barriuso R., Fernández de Larrea N. et al. Serum phospholipid fatty acids levels, anthropometric variables and adiposity in spanish premenopausal women. Nutrients. 2020June25;12(6):1895. DOI: 10.3390/nu12061895.Lope V., Del Pozo M.D.P., Lope V., Criado-Navarro I., Pastor-Barriuso R., Fernández de Larrea N. et al. Serum phospholipid fatty acids levels, anthropometric variables and adiposity in spanish premenopausal women. Nutrients. 2020June25;12(6):1895. DOI: 10.3390/nu12061895.Yamazaki Y., Kondo K., Maeba R., Nishimukai M., Nezu T., Hara H. Proportion of nervonic acid in serum lipids is associated with serum plasmalogen levels and metabolic syndrome. J. Oleo Sci. 2014;63(5):527–537. DOI: 10.5650/jos.ess13226.Yamazaki Y., Kondo K., Maeba R., Nishimukai M., Nezu T., Hara H. Proportion of nervonic acid in serum lipids is associated with serum plasmalogen levels and metabolic syndrome. J. Oleo Sci. 2014;63(5):527–537. DOI: 10.5650/jos.ess13226.Gogna N., Krishna M., Oommen A.M., Dorai K. Investigating correlations in the altered metabolic profiles of obese and diabetic subjects in a South Indian Asian population using an NMR-based metabolomic approach. Mol. Biosyst. 2015Feb.;11(2):595–606. DOI: 10.1039/c4mb00507d.Gogna N., Krishna M., Oommen A.M., Dorai K. Investigating correlations in the altered metabolic profiles of obese and diabetic subjects in a South Indian Asian population using an NMR-based metabolomic approach. Mol. Biosyst. 2015Feb.;11(2):595–606. DOI: 10.1039/c4mb00507d.Choromańska B., Myśliwiec P., Razak Hady H., Dadan J., Myśliwiec H., Chabowski A. et al. Metabolic syndrome is associated with ceramide accumulation in visceral adipose tissue of women with morbid obesity. Obesity (Silver Spring). 2019March;27(3):444–453. DOI: 10.1002/oby.22405.Choromańska B., Myśliwiec P., Razak Hady H., Dadan J., Myśliwiec H., Chabowski A. et al. Metabolic syndrome is associated with ceramide accumulation in visceral adipose tissue of women with morbid obesity. Obesity (Silver Spring). 2019March;27(3):444–453. DOI: 10.1002/oby.22405.Ma Y., Xiong J., Zhang X., Qiu T., Pang H., Li X. et al. Potential biomarker in serum for predicting susceptibility to type 2 diabetes mellitus: Free fatty acid 22:6. J. Diabetes Investig. 2021June;12(6):950–962. DOI: 10.1111/jdi.13443.Ma Y., Xiong J., Zhang X., Qiu T., Pang H., Li X. et al. Potential biomarker in serum for predicting susceptibility to type 2 diabetes mellitus: Free fatty acid 22:6. J. Diabetes Investig. 2021June;12(6):950–962. DOI: 10.1111/jdi.13443.Fretts A.M., Imamura F., Marklund M., Micha R., Wu J.H.Y., Murphy R.A. et al. Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies. Am. J. Clin. Nutr. 2019Apr.1;109(4):1216–1223. DOI: 10.1093/ajcn/nqz005.Fretts A.M., Imamura F., Marklund M., Micha R., Wu J.H.Y., Murphy R.A. et al. Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies. Am. J. Clin. Nutr. 2019Apr.1;109(4):1216–1223. DOI: 10.1093/ajcn/nqz005.Murphy M.P. Mitochondrial dysfunction indirectly elevates ROS production by the endoplasmic reticulum. Cell Metab. 2013;18(2):145–146. DOI: 10.1016/j.cmet.2013.07.006.Murphy M.P. Mitochondrial dysfunction indirectly elevates ROS production by the endoplasmic reticulum. Cell Metab. 2013;18(2):145–146. DOI: 10.1016/j.cmet.2013.07.006.Mihalik S.J., Goodpaster B.H., Kelley D.E., Chace D.H., Vockley J., Toledo F.G. et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010Sept.;18(9):1695–1700. DOI: 10.1038/oby.2009.510.Mihalik S.J., Goodpaster B.H., Kelley D.E., Chace D.H., Vockley J., Toledo F.G. et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010Sept.;18(9):1695–1700. DOI: 10.1038/oby.2009.510.Koves T.R., Ussher J.R., Noland R.C., Slentz D., Mosedale M., Ilkayeva O. et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008;7(1):45–56. DOI: 10.1016/j.cmet.2007.10.013.Koves T.R., Ussher J.R., Noland R.C., Slentz D., Mosedale M., Ilkayeva O. et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008;7(1):45–56. DOI: 10.1016/j.cmet.2007.10.013.Sharma S., Black S.M. Carnitine homeostasis, mitochondrial function, and cardiovascular disease. Drug Discov. Today Dis. Mech. 2009;6(1-4):e31–e39. DOI: 10.1016/j.ddmec.2009.02.001.Sharma S., Black S.M. Carnitine homeostasis, mitochondrial function, and cardiovascular disease. Drug Discov. Today Dis. Mech. 2009;6(1-4):e31–e39. DOI: 10.1016/j.ddmec.2009.02.001.Beyene H.B., Olshansky G., Giles C., Huynh K., Cinel M., Mellett N.A. et al. Lipidomic Signatures of Changes in Adiposity: A Large Prospective Study of 5849 Adults from the Australian Diabetes, Obesity and Lifestyle Study. Metabolites. 2021Sept.21;11(9):646. DOI: 10.3390/metabo11090646.Beyene H.B., Olshansky G., Giles C., Huynh K., Cinel M., Mellett N.A. et al. Lipidomic Signatures of Changes in Adiposity: A Large Prospective Study of 5849 Adults from the Australian Diabetes, Obesity and Lifestyle Study. Metabolites. 2021Sept.21;11(9):646. DOI: 10.3390/metabo11090646.Zhao S., Feng X.F., Huang T., Luo H.H., Chen J.X., Zeng J. et al. The association between acylcarnitine metabolites and cardiovascular disease in chinese patients with type 2 diabetes mellitus. Front. Endocrinol. (Lausanne). 2020May5;11:212. DOI: 10.3389/fendo.2020.00212.Zhao S., Feng X.F., Huang T., Luo H.H., Chen J.X., Zeng J. et al. The association between acylcarnitine metabolites and cardiovascular disease in chinese patients with type 2 diabetes mellitus. Front. Endocrinol. (Lausanne). 2020May5;11:212. DOI: 10.3389/fendo.2020.00212.Schooneman M.G., Vaz F.M., Houten S.M., Soeters M.R. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes. 2013Jan.;62(1):1–8. DOI: 10.2337/db12-0466.Schooneman M.G., Vaz F.M., Houten S.M., Soeters M.R. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes. 2013Jan.;62(1):1–8. DOI: 10.2337/db12-0466.Taghizadeh H., Emamgholipour S., Hosseinkhani S., Arjmand B., Rezaei N., Dilmaghani-Marand A. et al. The association between acylcarnitine and amino acids profile and metabolic syndrome and its components in Iranian adults: Data from STEPs 2016. Front. Endocrinol. (Lausanne). 2023Feb.27;14:1058952. DOI: 10.3389/fendo.2023.1058952.Taghizadeh H., Emamgholipour S., Hosseinkhani S., Arjmand B., Rezaei N., Dilmaghani-Marand A. et al. The association between acylcarnitine and amino acids profile and metabolic syndrome and its components in Iranian adults: Data from STEPs 2016. Front. Endocrinol. (Lausanne). 2023Feb.27;14:1058952. DOI: 10.3389/fendo.2023.1058952.Beyene H.B., Olshansky G.T., Smith A.A., Giles C., Huynh K., Cinel M. et al. High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies. PLoS Biol. 2020Sept.28;18(9):e3000870. DOI: 10.1371/journal.pbio.3000870.Beyene H.B., Olshansky G.T., Smith A.A., Giles C., Huynh K., Cinel M. et al. High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies. PLoS Biol. 2020Sept.28;18(9):e3000870. DOI: 10.1371/journal.pbio.3000870.Fikri A.M., Smyth R., Kumar V., Al-Abadla Z., Abusnana S., Munday M.R. Pre-diagnostic biomarkers of type 2 diabetes identified in the UAE’s obese national population using targeted metabolomics. Sci. Rep. 2020Oct.19;10(1):17616. DOI: 10.1038/s41598-020-73384-7.Fikri A.M., Smyth R., Kumar V., Al-Abadla Z., Abusnana S., Munday M.R. Pre-diagnostic biomarkers of type 2 diabetes identified in the UAE’s obese national population using targeted metabolomics. Sci. Rep. 2020Oct.19;10(1):17616. DOI: 10.1038/s41598-020-73384-7.Telle-Hansen V.H., Christensen J.J., Formo G.A., Holven K.B., Ulven S.M. A comprehensive metabolic profiling of the metabolically healthy obesity phenotype. Lipids Health Dis. 2020May9;19(1):90. DOI: 10.1186/s12944-020-01273-z.Telle-Hansen V.H., Christensen J.J., Formo G.A., Holven K.B., Ulven S.M. A comprehensive metabolic profiling of the metabolically healthy obesity phenotype. Lipids Health Dis. 2020May9;19(1):90. DOI: 10.1186/s12944-020-01273-z.Дылева Ю.А., Груздева О.В., Белик Е.В. Церамиды: фокус на ожирение. Ожирение и метаболизм. 2020;17(3):307– 315. DOI: 10.14341/omet12565.Дылева Ю.А., Груздева О.В., Белик Е.В. Церамиды: фокус на ожирение. Ожирение и метаболизм. 2020;17(3):307– 315. DOI: 10.14341/omet12565.Green C.D., Maceyka M., Cowart L.A., Spiegel S. Sphingolipids in metabolic disease: The good, the bad, and the unknown. Cell Metab. 2021July6;33(7):1293–1306. DOI: 10.1016/j.cmet.2021.06.006.Green C.D., Maceyka M., Cowart L.A., Spiegel S. Sphingolipids in metabolic disease: The good, the bad, and the unknown. Cell Metab. 2021July6;33(7):1293–1306. DOI: 10.1016/j.cmet.2021.06.006.Chew W.S., Torta F., Ji S., Choi H., Begum H., Sim X. et al. Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence. JCI Insight. 2019June4;5(13):e126925. DOI: 10.1172/jci.insight.126925.Chew W.S., Torta F., Ji S., Choi H., Begum H., Sim X. et al. Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence. JCI Insight. 2019June4;5(13):e126925. DOI: 10.1172/jci.insight.126925.Lind L., Ahmad S., Elmståhl S., Fall T. The metabolic profile of waist to hip ratio-A multi-cohort study. PLoS One. 2023Feb.27;18(2):e0282433. DOI: 10.1371/journal.pone.0282433.Lind L., Ahmad S., Elmståhl S., Fall T. The metabolic profile of waist to hip ratio-A multi-cohort study. PLoS One. 2023Feb.27;18(2):e0282433. DOI: 10.1371/journal.pone.0282433.Ahmad S., Hammar U., Kennedy B., Salihovic S., Ganna A., Lind L. et al. Effect of General Adiposity and Central Body Fat Distribution on the Circulating Metabolome: A Multicohort Nontargeted Metabolomics Observational and Mendelian Randomization Study. Diabetes. 2022Feb.1;71(2):329–339. DOI: 10.2337/db20-1120.Ahmad S., Hammar U., Kennedy B., Salihovic S., Ganna A., Lind L. et al. Effect of General Adiposity and Central Body Fat Distribution on the Circulating Metabolome: A Multicohort Nontargeted Metabolomics Observational and Mendelian Randomization Study. Diabetes. 2022Feb.1;71(2):329–339. DOI: 10.2337/db20-1120.Weir J.M., Wong G., Barlow C.K., Greeve M.A., Kowalczyk A., Almasy L. et al. Plasma lipid profiling in a large population-based cohort. J. Lipid Res. 2013Oct.;54(10):2898– 2908. DOI: 10.1194/jlr.P035808.Weir J.M., Wong G., Barlow C.K., Greeve M.A., Kowalczyk A., Almasy L. et al. Plasma lipid profiling in a large population-based cohort. J. Lipid Res. 2013Oct.;54(10):2898– 2908. DOI: 10.1194/jlr.P035808.Liang X., Tang X., Xi B., Qu P., Ren Y., Hao G. Abdominal obesity-related lipid metabolites may mediate the association between obesity and glucose dysregulation. Pediatr. Res. 2023Jan.;93(1):183–188. DOI: 10.1038/s41390-022-02074-z.Liang X., Tang X., Xi B., Qu P., Ren Y., Hao G. Abdominal obesity-related lipid metabolites may mediate the association between obesity and glucose dysregulation. Pediatr. Res. 2023Jan.;93(1):183–188. DOI: 10.1038/s41390-022-02074-z.Tulipani S., Palau-Rodriguez M., Miñarro Alonso A., Cardona F., Marco-Ramell A., Zonja B. et al. Biomarkers of morbid obesity and prediabetes by metabolomic profiling of human discordant phenotypes. Clin. Chim. Acta. 2016Dec.1;463:53– 61. DOI: 10.1016/j.cca.2016.10.005.Tulipani S., Palau-Rodriguez M., Miñarro Alonso A., Cardona F., Marco-Ramell A., Zonja B. et al. Biomarkers of morbid obesity and prediabetes by metabolomic profiling of human discordant phenotypes. Clin. Chim. Acta. 2016Dec.1;463:53– 61. DOI: 10.1016/j.cca.2016.10.005.Wang Y., Jiang C.T., Song J.Y., Song Q.Y., Ma J., Wang H.J. Lipidomic profile revealed the association of plasma lysophosphatidylcholines with adolescent obesity. Biomed. Res. Int. 2019Dec.13;2019:1382418. DOI: 10.1155/2019/1382418.Wang Y., Jiang C.T., Song J.Y., Song Q.Y., Ma J., Wang H.J. Lipidomic profile revealed the association of plasma lysophosphatidylcholines with adolescent obesity. Biomed. Res. Int. 2019Dec.13;2019:1382418. DOI: 10.1155/2019/1382418.Yin R., Wang X., Li K., Yu K., Yang L. Lipidomic profiling reveals distinct differences in plasma lipid composition in overweight or obese adolescent students. BMC Endocr. Disord. 2021Oct.3;21(1):201. DOI: 10.1186/s12902-021-00859-7.Yin R., Wang X., Li K., Yu K., Yang L. Lipidomic profiling reveals distinct differences in plasma lipid composition in overweight or obese adolescent students. BMC Endocr. Disord. 2021Oct.3;21(1):201. DOI: 10.1186/s12902-021-00859-7.Pikó P., Pál L., Szűcs S., Kósa Z., Sándor J., Ádány R. Obesity-related changes in human plasma lipidome determined by the lipidyzer platform. Biomolecules. 2021Feb.21;11(2):326. DOI: 10.3390/biom11020326.Pikó P., Pál L., Szűcs S., Kósa Z., Sándor J., Ádány R. Obesity-related changes in human plasma lipidome determined by the lipidyzer platform. Biomolecules. 2021Feb.21;11(2):326. DOI: 10.3390/biom11020326.Bagheri M., Djazayery A., Farzadfar F., Qi L., Yekaninejad M.S., Aslibekyan S. et al. Plasma metabolomic profiling of amino acids and polar lipids in Iranian obese adults. Lipids Health Dis. 2019Apr.9;18(1):94. DOI: 10.1186/s12944-019-1037-0.Bagheri M., Djazayery A., Farzadfar F., Qi L., Yekaninejad M.S., Aslibekyan S. et al. Plasma metabolomic profiling of amino acids and polar lipids in Iranian obese adults. Lipids Health Dis. 2019Apr.9;18(1):94. DOI: 10.1186/s12944-019-1037-0.Werner E.R., Keller M.A., Sailer S., Lackner K., Koch J., Hermann M. et al. The TMEM189 gene encodes plasmanylethanolamine desaturase which introduces the characteristic vinyl ether double bond into plasmalogens. Proc. Natl. Acad. Sci. U.S.A. 2020Apr.7;117(14):7792–7798. DOI: 10.1073/pnas.1917461117Werner E.R., Keller M.A., Sailer S., Lackner K., Koch J., Hermann M. et al. The TMEM189 gene encodes plasmanylethanolamine desaturase which introduces the characteristic vinyl ether double bond into plasmalogens. Proc. Natl. Acad. Sci. U.S.A. 2020Apr.7;117(14):7792–7798. DOI: 10.1073/pnas.1917461117Huynh K., Barlow C.K., Jayawardana K.S., Weir J.M., Mellett N.A., Cinel M. et al. High-throughput plasma lipidomics: detailed mapping of the associations with cardiometabolic risk factors. Cell Chem. Biol. 2019Jan.17;26(1):71–84.e4. DOI: 10.1016/j.chembiol.2018.10.008.Huynh K., Barlow C.K., Jayawardana K.S., Weir J.M., Mellett N.A., Cinel M. et al. High-throughput plasma lipidomics: detailed mapping of the associations with cardiometabolic risk factors. Cell Chem. Biol. 2019Jan.17;26(1):71–84.e4. DOI: 10.1016/j.chembiol.2018.10.008.Bagheri M., Farzadfar F., Qi L., Yekaninejad M.S., Chamari M., Zeleznik O.A. et al. Obesity-related metabolomic profiles and discrimination of metabolically unhealthy obesity. J. Proteome Res. 2018Apr.6;17(4):1452–1462. DOI: 10.1021/acs.jproteome.7b00802.Bagheri M., Farzadfar F., Qi L., Yekaninejad M.S., Chamari M., Zeleznik O.A. et al. Obesity-related metabolomic profiles and discrimination of metabolically unhealthy obesity. J. Proteome Res. 2018Apr.6;17(4):1452–1462. DOI: 10.1021/acs.jproteome.7b00802.Nishida Y., Nishijima K., Yamada Y., Tanaka H., Matsumoto A., Fan J. et al. Whole-body insulin resistance and energy expenditure indices, serum lipids, and skeletal muscle metabolome in a state of lipoprotein lipaseoverexpression. Metabolomics. 2021Feb.16;17(3):26. DOI: 10.1007/s11306-021-01777-4.Nishida Y., Nishijima K., Yamada Y., Tanaka H., Matsumoto A., Fan J. et al. Whole-body insulin resistance and energy expenditure indices, serum lipids, and skeletal muscle metabolome in a state of lipoprotein lipaseoverexpression. Metabolomics. 2021Feb.16;17(3):26. DOI: 10.1007/s11306-021-01777-4.Ferrara P.J., Rong X., Maschek J.A., Verkerke A.R., Siripoksup P., Song H. et al. Lysophospholipid acylation modulates plasma membrane lipid organization and insulin sensitivity in skeletal muscle. J. Clin. Invest. 2021Apr.15;131(8):e135963. DOI: 10.1172/JCI135963.Ferrara P.J., Rong X., Maschek J.A., Verkerke A.R., Siripoksup P., Song H. et al. Lysophospholipid acylation modulates plasma membrane lipid organization and insulin sensitivity in skeletal muscle. J. Clin. Invest. 2021Apr.15;131(8):e135963. DOI: 10.1172/JCI135963.Lange M., Angelidou G., Ni Z., Criscuolo A., Schiller J., Blüher M. et al. AdipoAtlas: A reference lipidome for human white adipose tissue. Cell Rep. Med. 2021Sept.22;2(10): 100407. DOI: 10.1016/j.xcrm.2021.100407.Lange M., Angelidou G., Ni Z., Criscuolo A., Schiller J., Blüher M. et al. AdipoAtlas: A reference lipidome for human white adipose tissue. Cell Rep. Med. 2021Sept.22;2(10): 100407. DOI: 10.1016/j.xcrm.2021.100407.Kotronen A., Seppänen-Laakso T., Westerbacka J., Kiviluoto T., Arola J., Ruskeepää A.L. et al. Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity (Silver Spring). 2010May;18(5):937–944. DOI: 10.1038/oby.2009.326.Kotronen A., Seppänen-Laakso T., Westerbacka J., Kiviluoto T., Arola J., Ruskeepää A.L. et al. Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity (Silver Spring). 2010May;18(5):937–944. DOI: 10.1038/oby.2009.326.Lahelma M., Qadri S., Ahlholm N., Porthan K., Ruuth M., Juuti A. et al. The human liver lipidome is significantly related to the lipid composition and aggregation susceptibility of low-density lipoprotein (LDL) particles. Atherosclerosis. 2022Dec.;363:22–29. DOI: 10.1016/j.atherosclerosis.2022.11.018.Lahelma M., Qadri S., Ahlholm N., Porthan K., Ruuth M., Juuti A. et al. The human liver lipidome is significantly related to the lipid composition and aggregation susceptibility of low-density lipoprotein (LDL) particles. Atherosclerosis. 2022Dec.;363:22–29. DOI: 10.1016/j.atherosclerosis.2022.11.018.Lytle K.A., Chung J.O., Bush N.C., Triay J.M., Jensen M.D. Ceramide concentrations in liver, plasma, and very low-density lipoproteins of humans with severe obesity. Lipids. 2023Feb.27. DOI: 10.1002/lipd.12367.Lytle K.A., Chung J.O., Bush N.C., Triay J.M., Jensen M.D. Ceramide concentrations in liver, plasma, and very low-density lipoproteins of humans with severe obesity. Lipids. 2023Feb.27. DOI: 10.1002/lipd.12367.Leandro A.C., Michael L.F., Almeida M., Kuokkanen M., Huynh K., Giles C. et al. influence of the human lipidome on epicardial fat volume in Mexican American individuals. Front. Cardiovasc. Med. 2022June;9:889985. DOI: 10.3389/fcvm.2022.889985.Leandro A.C., Michael L.F., Almeida M., Kuokkanen M., Huynh K., Giles C. et al. influence of the human lipidome on epicardial fat volume in Mexican American individuals. Front. Cardiovasc. Med. 2022June;9:889985. DOI: 10.3389/fcvm.2022.889985.Błachnio-Zabielska A.U., Baranowski M., Hirnle T., Zabielski P., Lewczuk A., Dmitruk I. et al. Increased bioactive lipids content in human subcutaneous and epicardial fat tissue correlates with insulin resistance. Lipids. 2012Dec.;47(12):1131– 1141. DOI: 10.1007/s11745-012-3722-x.Błachnio-Zabielska A.U., Baranowski M., Hirnle T., Zabielski P., Lewczuk A., Dmitruk I. et al. Increased bioactive lipids content in human subcutaneous and epicardial fat tissue correlates with insulin resistance. Lipids. 2012Dec.;47(12):1131– 1141. DOI: 10.1007/s11745-012-3722-x.Tomášová P., Čermáková M., Pelantová H., Vecka M., Kratochvílová H., Lipš M. et al. Lipid profiling in epicardial and subcutaneous adipose tissue of patients with coronary artery disease. J. Proteome Res. 2020Oct.2;19(10):3993–4003. DOI: 10.1021/acs.jproteome.0c00269.Tomášová P., Čermáková M., Pelantová H., Vecka M., Kratochvílová H., Lipš M. et al. Lipid profiling in epicardial and subcutaneous adipose tissue of patients with coronary artery disease. J. Proteome Res. 2020Oct.2;19(10):3993–4003. DOI: 10.1021/acs.jproteome.0c00269.Al-Sari N., Suvitaival T., Mattila I., Ali A., Ahonen L., Trost K. et al. Lipidomics of human adipose tissue reveals diversity between body areas. PLoS One. 2020June16;15(6): e0228521. DOI: 10.1371/journal.pone.0228521.Al-Sari N., Suvitaival T., Mattila I., Ali A., Ahonen L., Trost K. et al. Lipidomics of human adipose tissue reveals diversity between body areas. PLoS One. 2020June16;15(6): e0228521. DOI: 10.1371/journal.pone.0228521.Hannich J.T., Loizides-Mangold U., Sinturel F., Harayama T., Vandereycken B., Saini C. et al. Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients. Acta Physiol. (Oxford). 2021May;232(1):e13610. DOI: 10.1111/apha.13610.Hannich J.T., Loizides-Mangold U., Sinturel F., Harayama T., Vandereycken B., Saini C. et al. Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients. Acta Physiol. (Oxford). 2021May;232(1):e13610. DOI: 10.1111/apha.13610.Kolak M., Westerbacka J., Velagapudi V.R., Wågsäter D., Yetukuri L., Makkonen J. et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes. 2007Aug.;56(8):1960–1968. DOI: 10.2337/db07-0111.Kolak M., Westerbacka J., Velagapudi V.R., Wågsäter D., Yetukuri L., Makkonen J. et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes. 2007Aug.;56(8):1960–1968. DOI: 10.2337/db07-0111.Chaurasia B., Kaddai V.A., Lancaster G.I., Henstridge D.C., Sriram S., Galam D.L. et al. Adipocyte ceramides regulate subcutaneous adipose browning, inflammation, and metabolism. Cell Metab. 2016Dec.13;24(6):820–834. doi: 10.1016/j.cmet.2016.10.002.Chaurasia B., Kaddai V.A., Lancaster G.I., Henstridge D.C., Sriram S., Galam D.L. et al. Adipocyte ceramides regulate subcutaneous adipose browning, inflammation, and metabolism. Cell Metab. 2016Dec.13;24(6):820–834. doi: 10.1016/j.cmet.2016.10.002.Chathoth S., Ismail M.H., Alghamdi H.M., Zakaria H.M., Hassan K.A., Alshomimi S. et al. Insulin resistance induced by de novo pathway-generated C16-ceramide is associated with type 2 diabetes in an obese population. Lipids Health Dis. 2022Feb.20;21(1):24. DOI: 10.1186/s12944-022-01634-w.Chathoth S., Ismail M.H., Alghamdi H.M., Zakaria H.M., Hassan K.A., Alshomimi S. et al. Insulin resistance induced by de novo pathway-generated C16-ceramide is associated with type 2 diabetes in an obese population. Lipids Health Dis. 2022Feb.20;21(1):24. DOI: 10.1186/s12944-022-01634-w.Brusatori M., Wood M.H., Tucker S.C., Maddipati K.R., Koya S.K., Auner G.W. et al. Ceramide changes in abdominal subcutaneous and visceral adipose tissue among diabetic and nondiabetic patients. J. Diabetes. 2022Apr.;14(4):271–281. DOI: 10.1111/1753-0407.13262.Brusatori M., Wood M.H., Tucker S.C., Maddipati K.R., Koya S.K., Auner G.W. et al. Ceramide changes in abdominal subcutaneous and visceral adipose tissue among diabetic and nondiabetic patients. J. Diabetes. 2022Apr.;14(4):271–281. DOI: 10.1111/1753-0407.13262.Walker C.G., Browning L.M., Stecher L., West A.L., Madden J., Jebb S.A. et al. Fatty acid profile of plasma NEFA does not reflect adipose tissue fatty acid profile. Br. J. Nutr. 2015Sept.14;114(5):756–762. DOI: 10.1017/S0007114515002251.Walker C.G., Browning L.M., Stecher L., West A.L., Madden J., Jebb S.A. et al. Fatty acid profile of plasma NEFA does not reflect adipose tissue fatty acid profile. Br. J. Nutr. 2015Sept.14;114(5):756–762. DOI: 10.1017/S0007114515002251.Baila-Rueda L., Cenarro A., Lamiquiz-Moneo I., Marco-Benedi V., Gracia-Rubio I., Casamayor-Franco M.C. et al. Association of cholesterol and oxysterols in adipose tissue with obesity and metabolic syndrome traits. J. Clin. Endocrinol. Metab. 2022Aug.18;107(9):e3929–e3936. DOI: 10.1210/clinem/dgac188.Baila-Rueda L., Cenarro A., Lamiquiz-Moneo I., Marco-Benedi V., Gracia-Rubio I., Casamayor-Franco M.C. et al. Association of cholesterol and oxysterols in adipose tissue with obesity and metabolic syndrome traits. J. Clin. Endocrinol. Metab. 2022Aug.18;107(9):e3929–e3936. DOI: 10.1210/clinem/dgac188.Wu Z.E., Kruger M.C., Cooper G.J.S., Sequeira I.R., McGill A.T., Poppitt S.D. et al. Dissecting the relationship between plasma and tissue metabolome in a cohort of women with obesity: Analysis of subcutaneous and visceral adipose, muscle, and liver. FASEB J. 2022July;36(7):e22371. DOI: 10.1096/fj.202101812R.Wu Z.E., Kruger M.C., Cooper G.J.S., Sequeira I.R., McGill A.T., Poppitt S.D. et al. Dissecting the relationship between plasma and tissue metabolome in a cohort of women with obesity: Analysis of subcutaneous and visceral adipose, muscle, and liver. FASEB J. 2022July;36(7):e22371. DOI: 10.1096/fj.202101812R.Lanzon B., Martin-Taboada M., Castro-Alves V., VilaBedmar R., González de Pablos I., Duberg D. et al. Lipidomic and metabolomic signature of progression of chronic kidney disease in patients with severe obesity. Metabolites. 2021Dec.3;11(12):836. DOI: 10.3390/metabo11120836.Lanzon B., Martin-Taboada M., Castro-Alves V., VilaBedmar R., González de Pablos I., Duberg D. et al. Lipidomic and metabolomic signature of progression of chronic kidney disease in patients with severe obesity. Metabolites. 2021Dec.3;11(12):836. DOI: 10.3390/metabo11120836.Wu Z.E., Fraser K., Kruger M.C., Sequeira I.R., Yip W., Lu L.W. et al. Untargeted metabolomics reveals plasma metabolites predictive of ectopic fat in pancreas and liver as assessed by magnetic resonance imaging: the TOFI_Asia study. Int. J. Obes. (London). 2021Aug.;45(8):1844–1854. DOI: 10.1038/s41366-021-00854-x.Wu Z.E., Fraser K., Kruger M.C., Sequeira I.R., Yip W., Lu L.W. et al. Untargeted metabolomics reveals plasma metabolites predictive of ectopic fat in pancreas and liver as assessed by magnetic resonance imaging: the TOFI_Asia study. Int. J. Obes. (London). 2021Aug.;45(8):1844–1854. DOI: 10.1038/s41366-021-00854-x.Mayo R., Crespo J., Martínez-Arranz I., Banales J.M., Arias M., Mincholé I. et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol. Commun. 2018May4;2(7):807–820. DOI: 10.1002/hep4.1188.Mayo R., Crespo J., Martínez-Arranz I., Banales J.M., Arias M., Mincholé I. et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol. Commun. 2018May4;2(7):807–820. DOI: 10.1002/hep4.1188.Stegemann C., Pechlaner R., Willeit P., Langley S.R., Mangino M., Mayr U. et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014May6;129(18):1821–1831. DOI: 10.1161/CIRCULATIONAHA.113.002500.Stegemann C., Pechlaner R., Willeit P., Langley S.R., Mangino M., Mayr U. et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014May6;129(18):1821–1831. DOI: 10.1161/CIRCULATIONAHA.113.002500.Rhee E.P., Cheng S., Larson M.G., Walford G.A., Lewis G.D., McCabe E. et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J. Clin .Invest. 2011Apr.;121(4):1402–1411. DOI: 10.1172/JCI44442.Rhee E.P., Cheng S., Larson M.G., Walford G.A., Lewis G.D., McCabe E. et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J. Clin .Invest. 2011Apr.;121(4):1402–1411. DOI: 10.1172/JCI44442.Afshinnia F., Nair V., Lin J., Rajendiran T.M., Soni T., Byun J. et al. Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians. JCI Insight. 2019Nov.1;4(21):e130317. DOI: 10.1172/jci.insight.130317.Afshinnia F., Nair V., Lin J., Rajendiran T.M., Soni T., Byun J. et al. Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians. JCI Insight. 2019Nov.1;4(21):e130317. DOI: 10.1172/jci.insight.130317.Guo K., Savelieff M.G., Rumora A.E., Alakwaa F.M., Callaghan B.C., Hur J. et al. Plasma Metabolomics and lipidomics differentiate obese individuals by peripheral neuropathy status. J. Clin. Endocrinol. Metab. 2022March24;107(4):1091–1109. DOI: 10.1210/clinem/dgab844.Guo K., Savelieff M.G., Rumora A.E., Alakwaa F.M., Callaghan B.C., Hur J. et al. Plasma Metabolomics and lipidomics differentiate obese individuals by peripheral neuropathy status. J. Clin. Endocrinol. Metab. 2022March24;107(4):1091–1109. DOI: 10.1210/clinem/dgab844.Rumora A.E., Guo K., Alakwaa F.M., Andersen S.T., Reynolds E.L., Jørgensen M.E. et al. Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. Ann. Clin. Transl. Neurol. 2021June;8(6):1292–1307. DOI: 10.1002/acn3.51367.Rumora A.E., Guo K., Alakwaa F.M., Andersen S.T., Reynolds E.L., Jørgensen M.E. et al. Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. Ann. Clin. Transl. Neurol. 2021June;8(6):1292–1307. DOI: 10.1002/acn3.51367.Afshinnia F., Reynolds E.L., Rajendiran T.M., Soni T., Byun J., Savelieff M.G. et al. Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes. Ann. Clin. Transl. Neurol. 2022Sept.;9(9):1392–1404. DOI: 10.1002/acn3.51639.Afshinnia F., Reynolds E.L., Rajendiran T.M., Soni T., Byun J., Savelieff M.G. et al. Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes. Ann. Clin. Transl. Neurol. 2022Sept.;9(9):1392–1404. DOI: 10.1002/acn3.51639.Bihlmeyer N.A., Kwee L.C., Clish C.B., Deik A.A., Gerszten R.E., Pagidipati N.J. et al. Metabolomic profiling identifies complex lipid species and amino acid analogues associated with response to weight loss interventions. PLoS One. 2021May27;16(5):e0240764. DOI: 10.1371/journal.pone.0240764.Bihlmeyer N.A., Kwee L.C., Clish C.B., Deik A.A., Gerszten R.E., Pagidipati N.J. et al. Metabolomic profiling identifies complex lipid species and amino acid analogues associated with response to weight loss interventions. PLoS One. 2021May27;16(5):e0240764. DOI: 10.1371/journal.pone.0240764.Heidari Almasi M., Barzin M., Mahdavi M., Khalaj A., Ebrahimi D., Valizadeh M. et al. Comparing Effects of Bariatric Surgery on Body Composition Changes in Metabolically Healthy and Metabolically Unhealthy Severely Obese Patients: Tehran Obesity Treatment Study (TOTS). World J. Surg. 2023Jan.;47(1):209–216. DOI: 10.1007/s00268-022-06769-6.Heidari Almasi M., Barzin M., Mahdavi M., Khalaj A., Ebrahimi D., Valizadeh M. et al. Comparing Effects of Bariatric Surgery on Body Composition Changes in Metabolically Healthy and Metabolically Unhealthy Severely Obese Patients: Tehran Obesity Treatment Study (TOTS). World J. Surg. 2023Jan.;47(1):209–216. DOI: 10.1007/s00268-022-06769-6.Martínez-Sánchez M.A., Balaguer-Román A., FernándezRuiz V.E., Almansa-Saura S., García-Zafra V., Ferrer-Gómez M. et al. Plasma short-chain fatty acid changes after bariatric surgery in patients with severe obesity. Surg. Obes. Relat. Dis. 2023;19(7):727–734. DOI: 10.1016/j.soard.2022.12.041.Martínez-Sánchez M.A., Balaguer-Román A., FernándezRuiz V.E., Almansa-Saura S., García-Zafra V., Ferrer-Gómez M. et al. Plasma short-chain fatty acid changes after bariatric surgery in patients with severe obesity. Surg. Obes. Relat. Dis. 2023;19(7):727–734. DOI: 10.1016/j.soard.2022.12.041.Trivedi N., Erickson H.E., Bala V., Chhonker Y.S., Murry D.J. A Concise Review of Liquid Chromatography-Mass Spectrometry-Based Quantification Methods for Short Chain Fatty Acids as Endogenous Biomarkers. Int. J. Mol. Sci. 2022Nov.3;23(21):13486. DOI: 10.3390/ijms232113486.Trivedi N., Erickson H.E., Bala V., Chhonker Y.S., Murry D.J. A Concise Review of Liquid Chromatography-Mass Spectrometry-Based Quantification Methods for Short Chain Fatty Acids as Endogenous Biomarkers. Int. J. Mol. Sci. 2022Nov.3;23(21):13486. DOI: 10.3390/ijms232113486.Liakh I., Proczko-Stepaniak M., Sledzinski M., Mika A. Serum free fatty acid levels and insulin resistance in patients undergoing one-anastomosis gastric bypass. Wideochir inne tech maloinwazyjne. 2022March;17(1):194–198. DOI: 10.5114/wiitm.2021.107754.Liakh I., Proczko-Stepaniak M., Sledzinski M., Mika A. Serum free fatty acid levels and insulin resistance in patients undergoing one-anastomosis gastric bypass. Wideochir inne tech maloinwazyjne. 2022March;17(1):194–198. DOI: 10.5114/wiitm.2021.107754.Balonov I., Kurlbaum M., Koschker A.C., Stier C., Fassnacht M., Dischinger U. Changes in Plasma Metabolomic Profile Following Bariatric Surgery, Lifestyle Intervention or Diet Restriction-Insights from Human and Rat Studies. Int. J. Mol. Sci. 2023Jan.25;24(3):2354. DOI: 10.3390/ijms24032354.Balonov I., Kurlbaum M., Koschker A.C., Stier C., Fassnacht M., Dischinger U. Changes in Plasma Metabolomic Profile Following Bariatric Surgery, Lifestyle Intervention or Diet Restriction-Insights from Human and Rat Studies. Int. J. Mol. Sci. 2023Jan.25;24(3):2354. DOI: 10.3390/ijms24032354.Pakiet A., Haliński Ł.P., Rostkowska O., Kaska Ł., ProczkoStepaniak M., Śledziński T. et al. The effects of one-anastomosis gastric bypass on fatty acids in the serum of patients with morbid obesity. Obes. Surg. 2021Oct.;31(10):4264–4271. DOI: 10.1007/s11695-021-05531-Pakiet A., Haliński Ł.P., Rostkowska O., Kaska Ł., ProczkoStepaniak M., Śledziński T. et al. The effects of one-anastomosis gastric bypass on fatty acids in the serum of patients with morbid obesity. Obes. Surg. 2021Oct.;31(10):4264–4271. DOI: 10.1007/s11695-021-05531-Lin C., Våge V., Mjøs S.A., Kvalheim O.M. Changes in serum fatty acid levels during the first year after bariatric surgery. Obes. Surg. 2016Aug.;26(8):1735–1742. DOI: 10.1007/s11695-015-1980-4.Lin C., Våge V., Mjøs S.A., Kvalheim O.M. Changes in serum fatty acid levels during the first year after bariatric surgery. Obes. Surg. 2016Aug.;26(8):1735–1742. DOI: 10.1007/s11695-015-1980-4.Mika A., Wilczynski M., Pakiet A., Kaska L., Proczko-Stepaniak M., Stankiewicz M. et al. Short-term effect of one-anastomosis gastric bypass on essential fatty acids in the serum of obese patients. Nutrients. 2020Jan.9;12(1):187. DOI: 10.3390/nu12010187.Mika A., Wilczynski M., Pakiet A., Kaska L., Proczko-Stepaniak M., Stankiewicz M. et al. Short-term effect of one-anastomosis gastric bypass on essential fatty acids in the serum of obese patients. Nutrients. 2020Jan.9;12(1):187. DOI: 10.3390/nu12010187.Ahlin S., Cefalo C., Bondia-Pons I., Trošt K., Capristo E., Marini L. et al. Metabolite changes after metabolic surgery – associations to parameters reflecting glucose homeostasis and lipid levels. Front. Endocrinol. (Lausanne). 2021Dec.16; 12:786952. DOI: 10.3389/fendo.2021.786952.Ahlin S., Cefalo C., Bondia-Pons I., Trošt K., Capristo E., Marini L. et al. Metabolite changes after metabolic surgery – associations to parameters reflecting glucose homeostasis and lipid levels. Front. Endocrinol. (Lausanne). 2021Dec.16; 12:786952. DOI: 10.3389/fendo.2021.786952.Yoshida N., Kitahama S., Yamashita T., Hirono Y., Tabata T., Saito Y. et al. Metabolic alterations in plasma after laparoscopic sleeve gastrectomy. J. Diabetes Investig. 2021Jan.;12(1):123–129. DOI: 10.1111/jdi.13328.Yoshida N., Kitahama S., Yamashita T., Hirono Y., Tabata T., Saito Y. et al. Metabolic alterations in plasma after laparoscopic sleeve gastrectomy. J. Diabetes Investig. 2021Jan.;12(1):123–129. DOI: 10.1111/jdi.13328.Lanzon B., Martin-Taboada M., Castro-Alves V., Vila-Bedmar R., González de Pablos I., Duberg D. et al. Lipidomic and metabolomic signature of progression of chronic kidney disease in patients with severe obesity. Metabolites. 2021Dec.3;11(12):836. DOI: 10.3390/metabo11120836.Lanzon B., Martin-Taboada M., Castro-Alves V., Vila-Bedmar R., González de Pablos I., Duberg D. et al. Lipidomic and metabolomic signature of progression of chronic kidney disease in patients with severe obesity. Metabolites. 2021Dec.3;11(12):836. DOI: 10.3390/metabo11120836.

The authors declare that there are no conflicts of interest present.